Search Results - "David, Olivier J."

Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers by Schmouder, Robert, Hariry, Sam, David, Olivier J.

“…Purpose Fingolimod (FTY720) is a sphingosine-1 phosphate-receptor (S1PR) modulator recently approved as a once-daily oral therapy for relapsing multiple…”
Get full text

Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338) by Petricoul, Olivier, Nazarian, Arman, Schuehly, Uwe, Schramm, Ursula, David, Olivier J., Laurent, Didier, Praestgaard, Jens, Roubenoff, Ronenn, Papanicolaou, Dimitris A., Rooks, Daniel

“…Background Bimagrumab is a human monoclonal antibody binding to the activin type II receptor with therapeutic potential in conditions of muscle wasting and…”
Get full text

Clinical Pharmacokinetics of Fingolimod by David, Olivier J., Kovarik, John M., Schmouder, Robert L.

“…Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compounds and is the first oral therapy approved…”
Get full text

Limited sampling strategies for estimating cyclosporin area under the concentration-time curve : Review of current algorithms by DAVID, Olivier J, JOHNSTON, Atholl

“…Cyclosporin, the drug of first choice in transplantation surgery, is characterized by a low therapeutic index and variable absorption, so close monitoring of…”
Get full text

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease by Neumann, Ulf, Ufer, Mike, Jacobson, Laura H, Rouzade‐Dominguez, Marie‐Laure, Huledal, Gunilla, Kolly, Carine, Lüönd, Rainer M, Machauer, Rainer, Veenstra, Siem J, Hurth, Konstanze, Rueeger, Heinrich, Tintelnot‐Blomley, Marina, Staufenbiel, Matthias, Shimshek, Derya R, Perrot, Ludovic, Frieauff, Wilfried, Dubost, Valerie, Schiller, Hilmar, Vogg, Barbara, Beltz, Karen, Avrameas, Alexandre, Kretz, Sandrine, Pezous, Nicole, Rondeau, Jean‐Michel, Beckmann, Nicolau, Hartmann, Andreas, Vormfelde, Stefan, David, Olivier J, Galli, Bruno, Ramos, Rita, Graf, Ana, Lopez Lopez, Cristina

“…The beta‐site amyloid precursor protein cleaving enzyme‐1 (BACE‐1) initiates the generation of amyloid‐β (Aβ), and the amyloid cascade leading to amyloid…”
Get full text

Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study by Boulton, Craig, Meiser, Karin, David, Olivier J., Schmouder, Robert

“…Fingolimod, a first-in-class oral sphingosine 1-phosphate receptor (S1PR) modulator, is approved in many countries for relapsing-remitting multiple sclerosis,…”
Get full text

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis by Yu, Huixin, Graham, Gordon, David, Olivier J., Kahn, Joseph M., Savelieva, Marina, Pigeolet, Etienne, Das Gupta, Ayan, Pingili, Ratnakar, Willi, Roman, Ramanathan, Krishnan, Kieseier, Bernd C., Häring, Dieter A., Bagger, Morten, Soelberg Sørensen, Per

“…Background Ofatumumab, a fully human anti-CD20 monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS), binds to a…”
Get full text

Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor by Skvara, Hans, Kalthoff, Frank, Meingassner, Josef G., Wolff-Winiski, Barbara, Aschauer, Heinrich, Kelleher, Joseph F., Wu, Xu, Pan, Shifeng, Mickel, Lesanka, Schuster, Christopher, Stary, Georg, Jalili, Ahmad, David, Olivier J., Emotte, Corinne, Antunes, Ana Monica Costa, Rose, Kristine, Decker, Jeremy, Carlson, Ilene, Gardner, Humphrey, Stuetz, Anton, Bertolino, Arthur P., Stingl, Georg, De Rie, Menno A.

“…Basal cell carcinoma (BCC) is a distinctive manifestation in nevoid basal cell carcinoma syndrome (NBCCS) patients. Both inherited and acquired mutations of…”
Get full text

Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers by Ocwieja, Magdalena, Meiser, Karin, David, Olivier J., Valencia, Jessica, Wagner, Frank, Schreiber, Stephan J., Pleyer, Uwe, Ziemer, Sabine, Schmouder, Robert

“…Aim Fingolimod, a sphingosine 1‐phosphate receptor modulator, is the first oral disease modifying therapy approved for the treatment of relapsing multiple…”
Get full text

Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects by David, Olivier J., Behrje, Rhett, Pal, Parasar, Hara, Hisanori, Lates, Christian D., Schmouder, Robert

“…This open‐label, single‐sequence study in healthy subjects investigated the effects of steady‐state carbamazepine on the pharmacokinetic (PK) profile of a…”
Get full text

Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study by David, Olivier J, Pryce, Maxwell, Meiser, Karin, Picard, Franck, Emotte, Corinne, Kobalava, Zhanna, Moiseev, Valentin, Schmouder, Robert

“…This study assessed the pharmacokinetics and tolerability of fingolimod and its metabolites in severe renal impairment and healthy subjects. In this…”
Get full text

Population Pharmacokinetics of Fingolimod Phosphate in Healthy Participants by Wu, Kai, Mercier, Francois, David, Olivier J., Schmouder, Robert L., Looby, Michael

“…Fingolimod (FTY720) is a sphingosine 1-phosphate receptor (S1PR) modulator currently being evaluated for the treatment of multiple sclerosis. Fingolimod…”
Get full text

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod by David, Olivier J., Berwick, Amy, Pezous, Nicole, Lang, Michael, Tiel‐Wilck, Klaus, Ziemssen, Tjalf, Li, Peng, Hara, Hisanori, Schmouder, Robert

“…The safety profile of fingolimod 0.5 mg, approved therapy for relapsing multiple sclerosis, is well established in clinical and real‐world studies. As…”
Get full text

Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results by David, Olivier J, Ocwieja, Magdalena, Meiser, Karin, Emotte, Corinne, Jakab, Annamaria, Wemer, Johan, den Daas, Izaak, Schmouder, Robert

“…Fingolimod has a novel mechanism of action in multiple sclerosis, being a first-in-class sphingosine 1-phosphate receptor modulator. Because of a potential…”
Get full text

Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma by Boulton, Craig, David, Olivier J., Meiser, Karin, Schmouder, Robert

“…Fingolimod, a first‐in‐class sphingosine 1‐phosphate receptor modulator, is the first approved oral therapy for relapsing multiple sclerosis (MS). While…”
Get full text

Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery by Banner, Nicholas R, David, Olivier J, Leaver, Neil, Davis, Julie, Breen, Jane, Johnston, Atholl, Yacoub, Magdi H

“…Neoral cyclosporine has better absorption characteristics than the original Sandimmun formulation. This has allowed Neoral to be administered orally in…”
Get more information

The BACE ‐1 inhibitor CNP 520 for prevention trials in Alzheimer's disease by Neumann, Ulf, Ufer, Mike, Jacobson, Laura H, Rouzade‐Dominguez, Marie‐Laure, Huledal, Gunilla, Kolly, Carine, Lüönd, Rainer M, Machauer, Rainer, Veenstra, Siem J, Hurth, Konstanze, Rueeger, Heinrich, Tintelnot‐Blomley, Marina, Staufenbiel, Matthias, Shimshek, Derya R, Perrot, Ludovic, Frieauff, Wilfried, Dubost, Valerie, Schiller, Hilmar, Vogg, Barbara, Beltz, Karen, Avrameas, Alexandre, Kretz, Sandrine, Pezous, Nicole, Rondeau, Jean‐Michel, Beckmann, Nicolau, Hartmann, Andreas, Vormfelde, Stefan, David, Olivier J, Galli, Bruno, Ramos, Rita, Graf, Ana, Lopez Lopez, Cristina

“…The beta‐site amyloid precursor protein cleaving enzyme‐1 (BACE‐1) initiates the generation of amyloid‐β (Aβ), and the amyloid cascade leading to amyloid…”
Get full text

Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study by Boulton, Craig, Meiser, Karin, David, Olivier J, Schmouder, Robert

Get full text